Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative
GEROSCIENCE
Authors: Canevelli, Marco; Arisi, Ivan; Bacigalupo, Ilaria; Arighi, Andrea; Galimberti, Daniela; Vanacore, Nicola; D'Onofrio, Mara; Cesari, Matteo; Bruno, Giuseppe
Abstract
The present study aimed at investigating if the main biomarkers of Alzheimer's disease (AD) neuropathology and their association with cognitive disturbances and dementia are modified by the individual's frailty status. We performed a cross-sectional analysis of data from participants with normal cognition, mild cognitive impairment (MCI), and AD dementia enrolled in the Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2) study. Frailty was operationalized by computing a 40-item Frailty Index (FI). The following AD biomarkers were considered and analyzed according to the participants' frailty status: CSF A beta(1-42), P-181-tau, and T-tau; MRI-based hippocampus volume; cortical glucose metabolism at the FDG PET imaging; amyloid deposition at the F-18-AV-45 PET imaging. Logistic regression models, adjusted for age, sex, and education, were performed to explore the association of biomarkers with cognitive status at different FI levels. Subjects with higher FI scores had lower CSF levels of A beta(1-42), hippocampus volumes at the MRI, and glucose metabolism at the FDG PET imaging, and a higher amyloid deposition at the F-18-AV-45 PET. No significant differences were observed among the two frailty groups concerning ApoE genotype, CSF T-tau, and P-tau. Increasing frailty levels were associated with a weakened relationship between dementia and F-18-AV-45 uptake and hippocampus volume and with a stronger relationship of dementia with FDG PET. Frailty contributes to the discrepancies between AD pathology and clinical manifestations and influences the association of AD pathological modifications with cognitive changes. AD and dementia should increasingly be conceived as "complex diseases of aging," determined by multiple, simultaneous, and interacting pathophysiological processes.
(B)over-bar(c) ->eta(c),(B)over-bar(c) -> J/psi and (B)over-bar -> D-(*()) semileptonic decays including new physics
PHYSICAL REVIEW D
Authors: Penalva, Neus; Hernandez, Eliecer; Nieves, Juan
Abstract
We apply the general formalism derived by Penalva et al. [Phys. Rev. D 101, 113004 (2020)] to the semileptonic decay of pseudoscalar mesons containing a b quark. While present (B) over bar -> D-(*()) data give the strongest evidence in favor of lepton flavor universality violation, the observables that are normally considered are not able to distinguish between different new physics (NP) scenarios. In the above reference we discussed the relevant role that the various contributions to the double differential decay widths d(2)Gamma (d omega d cos theta(l)) and d(2)Gamma (d omega dE(l)) could play to this end. Here omega is the product of the two hadron fourvelocities, theta(l) is the angle made by the final lepton and final hadron three-momenta in the center of mass of the final two-lepton system, and E-l is the final charged lepton energy in the laboratory system. The formalism was applied by Penalva et al. to the analysis of the Lambda(b) -> Lambda(c) semileptonic decay, showing the new observables were able to tell apart different NP scenarios. Here we analyze the (B) over barc -> eta(c)tau(nu) over bar (tau), (B) over barc -> J/psi tau(nu) over bar (tau), (B) over bar -> D tau(nu) over bar (tau) and (B) over bar -> D*tau(nu) over bar (tau) , semileptonic decays. We find that, as a general rule, the (B) over barc -> J/psi observables, even including (tau) polarization, are less optimal for distinguishing between NP scenarios than those obtained from (B) over barc -> eta(c) decays, or those presented by Penalva et al. for the related Lambda(b) -> Lambda(c) semileptonic decay. Finally, we show that (B) over bar -> D and (B) over barc -> eta(c) , and (B) over bar -> D* and (B) over barc -> J/psi decay observables exhibit similar behaviors.
COA
Publication 
 monoclonal Antibody, clone FQS3500.jpg)
 monoclonal Antibody, clone FQS3407.jpg)
 Antibody_1.gif)
Loading ......
